Crizotinib was approved to treat advanced NSCLC with rearranged anaplastic lymphoma kinase (ALK) or ROS1 gene [7, 8], and dabrafenib which targets a rare mutation in lung cancer (BRAF V600E) was approved for the treatment of BRAF-positive advanced NSCLC [9]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.